Stephen G Ellis
Ellis, Stephen Geoffrey 1951-....
Ellis, Stephen G. (Stephen Geoffrey), 1951-
Ellis, Stephen G.
Ellis, Stephen G. (Stephen Geoffrey)
Ellis, Stephen Geoffrey, 1951-...., cardiologue
Ellis, Stephen G. 1951-
VIAF ID: 85744338 (Personal)
Permalink: http://viaf.org/viaf/85744338
Preferred Forms
- 200 _ | ‡a Ellis ‡b Stephen Geoffrey ‡f 1951-....
-
- 100 1 _ ‡a Ellis, Stephen G. ‡d 1951-
- 100 1 _ ‡a Ellis, Stephen G. ‡q (Stephen Geoffrey)
-
- 100 1 0 ‡a Ellis, Stephen G. ‡q (Stephen Geoffrey), ‡d 1951-
-
-
-
- 100 1 _ ‡a Ellis, Stephen Geoffrey ‡d 1951-
- 100 1 _ ‡a Ellis, Stephen Geoffrey, ‡d 1951-...., ‡c cardiologue
- 100 0 _ ‡a Stephen G Ellis
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
Complications of coronary angioplasty | |
Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy). | |
Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial | |
Impaired myocardial perfusion score and inflammatory markers in patients undergoing primary angioplasty for acute myocardial infarction | |
Importance of Abnormal Chloride Homeostasis in Stable Chronic Heart Failure | |
Importance of case mix during training in interventional cardiology | |
The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularization in diabetics | |
In-hospital cardiac mortality after acute closure after coronary angioplasty: analysis of risk factors from 8,207 procedures | |
In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting? | |
Incomplete tooth fracture--proposal for a new definition | |
Increased coronary perforation in the new device era. Incidence, classification, management, and outcome | |
Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention | |
Incremental progress? The roles of direct stenting and routine troponin measurement after percutaneous coronary intervention | |
Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model | |
Influence of local delivery of the protein tyrosine kinase receptor inhibitor tyrphostin-47 on smooth-muscle cell proliferation in a rat carotid balloon-injury model | |
The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention | |
New frontiers in coronary stenting | |
Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial. | |
Percutaneous coronary revascularization in coronary artery disease: lessons from a single center experience | |
Percutaneous transvenous mitral annuloplasty: initial human experience with a novel coronary sinus implant device. | |
Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation | |
Prediction of Coronary Heart Disease Risk using a Genetic Risk Score: The Atherosclerosis Risk in Communities Study | |
Predictive models for short- and long-term adverse outcomes following discharge in a contemporary population with acute coronary syndromes | |
A randomized trial of 5 versus 7 French guiding catheters for transfemoral percutaneous coronary stent implantation. | |
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk | |
Renin-Angiotensin System Antagonists in Patients Without Left Ventricular Dysfunction After Percutaneous Intervention for ST-Segment Elevation Myocardial Infarction | |
Rescue percutaneous coronary intervention after failed fibrinolytic therapy: have expectations been met? | |
Restenosis after placement of Palmaz-Schatz stents in native coronary arteries. Initial results of a multicenter experience | |
Restenosis, statistics, and reasonable inferences. | |
Revascularization for unprotected left main disease: evolution of the evidence basis to redefine treatment standards | |
Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: insights from the RESCUE I, RESCUE II, and other contemporary clinical experiences | |
Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation | |
Risk factors, time course and treatment effect for restenosis after successful percutaneous transluminal coronary angioplasty of chronic total occlusion | |
Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty | |
Safety and efficacy of overlapping sirolimus-eluting versus paclitaxel-eluting stents | |
The safety of a bivalirudin-based approach in patients undergoing rotational atherectomy | |
Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency | |
Safety of "bridging" with eptifibatide for patients with coronary stents before cardiac and non-cardiac surgery | |
Safety of femoral closure devices after percutaneous coronary interventions in the era of glycoprotein IIb/IIIa platelet blockade | |
Serial intravascular ultrasound analysis of stent strut distribution and fracture: an integrated analysis of the taxus IV, V, and VI trials | |
Severe aortic stenosis and coronary artery disease--implications for management in the transcatheter aortic valve replacement era: a comprehensive review | |
Significance of a coronary artery with Thrombolysis in Myocardial infarction grade 2 flow “patency” | |
Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions | |
The sirolimus-eluting Cypher Select coronary stent for the treatment of bare-metal and drug-eluting stent restenosis: insights from the e-SELECT (Multicenter Post-Market Surveillance) registry | |
The State of the Absorb Bioresorbable Scaffold: Consensus From an Expert Panel | |
Stent-assisted detachable coil embolization of pseudoaneurysms in the coronary circulation. | |
Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT | |
Stent thrombosis with second-generation drug-eluting stents compared with bare-metal stents: network meta-analysis of primary percutaneous coronary intervention trials in ST-segment–elevation myocardial infarction [corrected]. | |
Stenting for ischemic heart disease | |
Stenting for ST-segment elevation myocardial infarction is associated with less neointimal hyperplasia in the pooled IVUS analysis from HORIZONS-AMI and the TAXUS IV and V and ATLAS workhorse, long lesion, and direct stent studies | |
Strategic approaches in coronary intervention | |
Studies of experimental coronary artery reperfusion. Effects on infarct size, myocardial function, biochemistry, ultrastructure and microvascular damage. | |
Subacute stent thrombosis: evolving issues and current concepts | |
Submaximal exercise thallium-201 SPECT for assessment of interventional therapy in patients with acute myocardial infarction | |
A survey of referrals to a restorative dentistry department in a district general hospital. | |
Sustained Local Delivery of Dexamethasone by a Novel Intravascular Eluting Stent to Prevent Restenosis in the Porcine Coronary Injury Model | |
Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease | |
Systemic Pharmacokinetics of Everolimus Eluted From the Absorb Bioresorbable Vascular Scaffold: An ABSORB III Substudy. | |
Systolic left ventricular function after reperfusion therapy for acute myocardial infarction. Analysis of determinants of improvement. The TAMI Study Group | |
TCT-823 Results from LateTIME: A Randomized, Placebo Controlled Trial of Intracoronary Stem Cell Delivery Two to Three Weeks Following Acute Myocardial Infarction from the Cardiovascular Cell Therapy Research Network | |
Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group | |
Thrombosis and drug-eluting stents: an objective appraisal | |
Thrombosis of a flexible coil coronary stent: frequency, predictors and clinical outcome | |
The TIME Trial - Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis | |
The Time-Varying Risk of Cardiovascular and Noncardiovascular Readmissions Early After Acute Myocardial Infarction. | |
The transcription factor GATA-2 does not associate with angiographic coronary artery disease in the Ottawa Heart Genomics and Cleveland Clinic GeneBank Studies |